| 64.93 1.08 (1.69%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 91.71 |
1-year : | 104.06 |
| Resists | First : | 78.52 |
Second : | 89.09 |
| Pivot price | 69.77  |
|||
| Supports | First : | 61.4 |
Second : | 51.09 |
| MAs | MA(5) : | 64.66 |
MA(20) : | 72.48 |
| MA(100) : | 43.03 |
MA(250) : | 26.56 |
|
| MACD | MACD : | -0.8 |
Signal : | 1 |
| %K %D | K(14,3) : | 12.5 |
D(3) : | 8.1 |
| RSI | RSI(14): 44.6 |
|||
| 52-week | High : | 99.41 | Low : | 8.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VKTX ] has closed above bottom band by 24.3%. Bollinger Bands are 19.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 67.69 - 68.02 | 68.02 - 68.31 |
| Low: | 62.74 - 63.1 | 63.1 - 63.43 |
| Close: | 64.33 - 64.93 | 64.93 - 65.48 |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Mon, 22 Apr 2024
Looking At Viking Therapeutics's Recent Unusual Options Activity - Viking Therapeutics (NASDAQ:VKTX) - Benzinga
Fri, 19 Apr 2024
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Thu, 18 Apr 2024
Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead (NASDAQ:VKTX) - Seeking Alpha
Wed, 17 Apr 2024
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 - Yahoo Finance
Wed, 10 Apr 2024
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Tue, 26 Mar 2024
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP ... - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 110 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 6 (%) |
| Held by Institutions | 71.4 (%) |
| Shares Short | 9,520 (K) |
| Shares Short P.Month | 12,280 (K) |
| EPS | -0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.5 % |
| Return on Equity (ttm) | -34.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -73 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -71.36 |
| PEG Ratio | -1.5 |
| Price to Book value | 18.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -97.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|